TCF25-Mediated Lysosomal Acidification and Cell Fate Under Glucose Starvation

Study Background and Research Question

Cellular adaptation to nutrient deprivation is a fundamental process in physiology and disease. Glucose, as the primary energy source, is tightly monitored, and its scarcity triggers complex metabolic rewiring. While autophagy and lysosomal catabolism are well-established responses to glucose starvation, the precise molecular regulators that coordinate metabolic adaptation and determine cell fate under these conditions remain incompletely understood. Ren et al. (2025) set out to identify critical mediators of cell survival and death under glucose limitation, focusing on the lysosomal pathway as a central node in nutrient sensing and cell fate decisions.

Key Innovation from the Reference Study

The pivotal innovation in this study is the identification of the transcription factor TCF25 as a nutrient sensor that orchestrates lysosomal acidification via V-type H⁺-ATPase (V-ATPase) activity during glucose deprivation. Through an unbiased genome-wide CRISPR-Cas9 screen, TCF25 emerged as an essential regulator of glucose-starvation-induced cell death. Mechanistically, TCF25 enhances lysosomal acidification by upregulating V-ATPase components, thereby supporting autophagic flux and metabolic adaptation when glucose is scarce. Under prolonged starvation, however, TCF25-mediated activation of ferritinophagy leads to increased lysosomal membrane permeability and lysosome-dependent cell death. This dual role highlights TCF25 as a critical switch between survival and programmed cell death in nutrient-stressed environments (Ren et al., 2025).

Methods and Experimental Design Insights

Ren et al. utilized a multi-tiered experimental design to dissect the role of TCF25. The initial genome-wide CRISPR-Cas9 loss-of-function screen was performed in human cell lines subjected to glucose starvation, with cell viability as the primary readout. Genes whose disruption conferred protection against starvation-induced death were enriched for those involved in lysosomal function. TCF25 was prioritized for further study based on its pronounced phenotype.

Subsequent experiments included:

• Genetic manipulation (knockout and overexpression) of TCF25 and selected V-ATPase subunits.
• Measurement of lysosomal acidification using pH-sensitive probes and imaging.
• Assessment of autophagic flux via LC3-II turnover and autophagosome-lysosome colocalization.
• Analysis of ferritinophagy and lysosomal membrane integrity using molecular markers and functional assays.
• In vivo validation in mouse models of hepatic ischemia-reperfusion injury (IRI), a clinically relevant context where nutrient deprivation and lysosomal cell death play significant roles.

This integrative approach allowed the authors to establish causality, dissect mechanistic pathways, and test physiological relevance.

Core Findings and Why They Matter

The main findings from Ren et al. (2025) can be summarized as follows:

• TCF25 as a Nutrient Sensor: TCF25 is required for glucose-starvation-induced cell death. Its loss reduces lysosomal acidification and confers resistance to nutrient stress.
• V-ATPase Activation: TCF25 directly or indirectly upregulates V-ATPase expression and/or assembly, resulting in increased proton transport and lysosomal acidification under glucose deprivation.
• Autophagic Adaptation: Enhanced lysosomal acidification supports autophagic degradation and energy recycling, enabling short-term survival during nutrient scarcity.
• Ferritinophagy and Lysosome-Dependent Cell Death: Prolonged activation of TCF25-mediated lysosomal pathways promotes ferritinophagy, leading to iron release, increased lysosomal membrane permeability, and cell death.
• In Vivo Protection: Mice deficient in TCF25 show reduced tissue damage in hepatic IRI, suggesting a protective effect against nutrient deprivation-induced cell death in vivo.

These results establish TCF25 as a central regulator linking nutrient sensing, lysosomal acidification, autophagy, and cell fate. Importantly, targeted disruption of TCF25 or V-ATPase activity can modulate the balance between adaptation and cell death, offering new therapeutic angles for metabolic diseases, ischemic injury, and cancer.

Comparison with Existing Internal Articles

Several internal articles provide complementary perspectives on the role of V-type H⁺-ATPase inhibitors in dissecting lysosomal and autophagic pathways. For example, "Concanamycin A: Mechanistic Precision for Cancer Research Innovation" explores how selective V-ATPase inhibition using Concanamycin A advances translational cancer biology by disrupting endosomal acidification and modulating apoptosis, closely paralleling the disruption of lysosomal function highlighted in the reference study.

Similarly, "Concanamycin A: V-type H+-ATPase Inhibitor for Cancer Research" offers practical guidance for implementing V-ATPase inhibitors to probe endosomal and lysosomal acidification, apoptosis induction in tumor cells, and experimental bottlenecks in cancer workflows. These resources reinforce the translational value of targeting lysosomal acidification—whether by genetic means (such as TCF25 knockout) or pharmacologically (via agents like Concanamycin A)—to dissect autophagic and cell death pathways.

Limitations and Transferability

As with any mechanistic study, several limitations merit consideration. First, while TCF25's regulatory role in lysosomal acidification and cell fate is robustly demonstrated in vitro and in a hepatic IRI mouse model, the generalizability to other tissues, tumor types, or chronic metabolic conditions will require further validation. Secondly, the precise molecular mechanism by which TCF25 controls V-ATPase assembly or activity is not fully elucidated, leaving open questions about potential cofactors or context-dependent regulation.

Pharmacological inhibition of V-ATPase mimics some aspects of TCF25 loss, but differences in specificity, timing, and off-target effects must be carefully controlled in translational applications. Overall, the findings provide a strong foundation for future studies examining the therapeutic potential of modulating lysosomal acidification and related cell death pathways.

Protocol Parameters

• TCF25 knockout/knockdown: Stable CRISPR-Cas9-mediated disruption or RNAi silencing in target cell lines prior to nutrient stress experiments.
• Glucose starvation: Culture in glucose-free media for 12–48 hours, with timepoints selected based on the cell type's sensitivity and experimental goals.
• Lysosomal acidification measurement: Use of ratiometric pH-sensitive dyes (e.g., LysoSensor) and confocal microscopy to quantify changes in lysosomal pH following genetic or pharmacological manipulation.
• V-ATPase inhibition control: Pharmacological inhibition using Concanamycin A at 20 nM for 60 minutes, as recommended in product documentation and internal workflow guides, to validate the involvement of V-ATPase in observed phenotypes.
• Ferritinophagy assessment: Immunoblotting for NCOA4, LC3-II, and ferritin heavy chain; evaluation of iron release and lysosomal membrane integrity under prolonged starvation.
• In vivo hepatic IRI modeling: TCF25 gene knockout mice subjected to partial hepatic ischemia-reperfusion, with histological and biochemical assessment of tissue injury.

Research Support Resources

For researchers aiming to interrogate the role of lysosomal acidification and V-ATPase function in metabolic adaptation, apoptosis induction in tumor cells, or cancer biology research, chemical tools such as Concanamycin A (SKU A8633) offer potent and selective inhibition of V-type H⁺-ATPase. According to the product information, Concanamycin A is effective at nanomolar concentrations and has been used in numerous workflows to study endosomal acidification, apoptosis, and tumor cell invasiveness. Researchers may refer to internal protocol guides and recent literature for optimal experimental designs and troubleshooting strategies.